|
45
|
240
|
4obzB |
Structure of cathepsin d with inhibitor 2-(3,4-dimethoxyphenyl)-n-[n-(4-methylbenzyl)carbamimidoyl]acetamide |
|
17
|
99
|
4nkkA |
Crystal structure of a multi-drug resistant clinical isolate-769 hiv-1 protease variant that is resistant to the dimerization inhibitory activity of tlf-paff |
|
49
|
240
|
4od9B |
Structure of cathepsin d with inhibitor n-(3,4-dimethoxybenzyl)-nalpha-{n-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl}-d-phenylalaninamide |
|
17
|
99
|
4obfA |
Crystal structure of nelfinavir-resistant, inactive hiv-1 protease variant (d30n/n88d) in complex with the p1-p6 substrate variant (s451n) |
|
17
|
97
|
4obzA |
Structure of cathepsin d with inhibitor 2-(3,4-dimethoxyphenyl)-n-[n-(4-methylbenzyl)carbamimidoyl]acetamide |
|
52
|
243
|
4oc6B |
Structure of cathepsin d with inhibitor 2-bromo-n-[(2s,3s)-4-{[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)propanoyl]amino}-3-hydroxy-1-(3-phenoxyphenyl)butan-2-yl]-4,5-dimethoxybenzamide |
|
19
|
99
|
4mc2A |
Hiv protease in complex with sa525p |
|
95
|
388
|
4lxmA |
Crystal structure of human beta secretase in complex with compound 12a |
|
19
|
99
|
4m8xA |
Gs-8374, a novel phosphonate-containing inhibitor of hiv-1 protease, effectively inhibits hiv pr mutants with amino acid insertions |
|
82
|
330
|
4lp9A |
Endothiapepsin complexed with phe-reduced-tyr peptide. |
|
18
|
99
|
4mc6A |
Hiv protease in complex with sa499 |
|
95
|
388
|
4lxkA |
Crystal structure of human beta secretase in complex with compound 11d |
|
18
|
99
|
4mc9A |
Hiv protease in complex with aa74 |
|
18
|
100
|
4m8yA |
Gs-8374, a novel phosphonate-containing inhibitor of hiv-1 protease, effectively inhibits hiv pr mutants with amino acid insertions |
|
18
|
99
|
4ll3A |
Structure of wild-type hiv protease in complex with darunavir |
|
20
|
99
|
4mc1A |
Hiv protease in complex with sa526p |
|
98
|
388
|
4lxaA |
Crystal structure of human beta secretase in complex with compound 11a |
|
86
|
330
|
4l6bA |
Endothiapepsin in complex with thiophen-based inhibitor sap128 |
|
16
|
99
|
4l1aA |
Crystallographic study of multi-drug resistant hiv-1 protease lopinavir complex: mechanism of drug recognition and resistance |
|
95
|
388
|
4k9hA |
Bace-1 inhibitor complex |
|
17
|
99
|
4l1aB |
Crystallographic study of multi-drug resistant hiv-1 protease lopinavir complex: mechanism of drug recognition and resistance |
|
18
|
99
|
4kb9A |
Crystal structure of wild-type hiv-1 protease with novel tricyclic p2-ligands grl-0739a |
|
103
|
388
|
4l7hA |
Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1) |
|
85
|
330
|
4lapA |
Endothiapepsin in complex with thiophen-based inhibitor sap114 |
|
104
|
388
|
4l7gA |
Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace1) |
|
100
|
391
|
4ke0A |
Crystal structure of bace1 in complex with hydroxyethylamine-macrocyclic inhibitor 13 |
|
19
|
99
|
4k4rA |
Tl-3 inhibited trp6ala hiv protease with 1-bromo-2-napthoic acid bound in exosite |
|
87
|
330
|
4lhhA |
Endothiapepsin in complex with 2mm acylhydrazone inhibitor |
|
88
|
330
|
4lbtA |
Endothiapepsin in complex with 100mm acylhydrazone inhibitor |
|
17
|
99
|
4k4qA |
Tl-3 inhibited trp6ala hiv protease with 3-bromo-2,6-dimethoxybenzoic acid bound in flap site |
|
104
|
402
|
4lc7A |
Aminooxazoline inhibitor of bace-1 |
|
93
|
387
|
4ke1A |
Crystal structure of bace1 in complex with hydroxyethylamine-macrocyclic inhibitor 19 |
|
18
|
99
|
4k4pA |
Tl-3 inhibited trp6ala hiv protease |
|
102
|
388
|
4l7jA |
Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1) |
|
90
|
330
|
4kupA |
Endothiapepsin in complex with 20mm acylhydrazone inhibitor |
|
96
|
388
|
4k8sA |
Hydroxyethylamine-based inhibitors of bace1: p1-p3 macrocyclization can improve potency, selectivity, and cell activity |
|
101
|
403
|
4i0jA |
Spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors |
|
106
|
402
|
4jooA |
Spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors |
|
103
|
390
|
4j0yA |
Crystal structure of bace-1 in complex with 5-cyano-pyridine-2-carboxylic acid [3-((4r,5s)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide |
|
20
|
99
|
4i8zA |
Crystal structure of wild type hiv-1 protease in complex with non-peptidic inhibitor, grl008 |
|
105
|
402
|
4jp9A |
Spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors |
|
96
|
397
|
4i12A |
Design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors |
|
104
|
390
|
4j0zA |
Crystal structure of bace-1 in complex with 5-cyano-pyridine-2-carboxylic acid [3-((4s,5r)-2-amino-5-fluoro-4-fluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide |
|
99
|
391
|
4ivtA |
Crystal structure of bace1 with its inhibitor |
|
100
|
401
|
4i0dA |
Design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors |
|
109
|
403
|
4hztA |
Structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates |
|
95
|
390
|
4j0pA |
Crystal structure of bace-1 in complex with 5-cyano-pyridine-2-carboxylic acid [3-((s)-2-amino-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide |
|
97
|
390
|
4j1kA |
Crystal structure of bace-1 in complex with 5-cyano-pyridine-2-carboxylic acid [3-((4r,5r,6s)-2-amino-5-fluoro-4-methyl-6-trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide |
|
104
|
400
|
4i0zA |
Structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates |
|
17
|
99
|
4j54A |
Crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20 with the potent antiviral inhibitor grl-0519a |
